This guidance from the World Health Organization (WHO) aims to provide a people-centred, evidence-based normative guideline that will support individuals, communities, and countries with quality health services and self-care interventions, based on PHC strategies, comprehensive essential service packages and people-centredness. The guidance includes a “strong” recommendation for self-administered injectable contraception, stating that this should be made available as an additional approach to deliver injectable contraception for individuals of reproductive age.
The Training Resource Package (TRP) for Family Planning’s Progestin-Only Injectable module includes sessions V and VI which are focused on DMPA-SC and self-injection, as well as a number of related handouts and resources. Developed in partnership with the Access Collaborative, these materials are intended for training health care providers who offer progestin-only injectable contraception (“injectables”) in the public or private sector.
The TRP website features training information and materials for a wide range of family planning methods. This includes curriculum components and tools for trainers to design, implement, and evaluate family planning and reproductive health training.
This publication recommends practical actions that countries can take at national, subregional and local levels to reorganize and safely maintain access to high-quality, essential health services in the pandemic context. The guidance outlines strategies governments should take to ensure populations retain access to essential health services, including sexual and reproductive health care, during and beyond the current COVID-19 pandemic. It is intended for decision-makers and managers at the national and subnational levels.
Along with the World Health Organization (WHO) Medical eligibility criteria for contraceptive use, this is one of two evidence-based guidance documents of the WHO’s initiative to develop and implement family planning guidelines for national programs. This document provides guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate. Safety considerations include common barriers to safe, correct and consistent use of contraception and the benefits of preventing unintended or unwanted pregnancy.
Along with the World Health Organization (WHO) Selected practice recommendations for contraceptive use this is one of two evidence-based guidance documents of the WHO’s initiative to develop and implement family planning guidelines for national programs. This publication provides guidance to national family planning and reproductive health programs in the preparation of guidelines for the delivery of contraceptive services. The guide provides information on the safety and use of intramuscular and subcutaneous DMPA.
This thesis provides an in-depth review of key World Health Organization-led procedures for registering medicines in developing countries, including prequalification, the concept of essential medicines, and collaborative registration.
The aim of this 35-page guide is to facilitate systematic planning for scaling up. It is intended for program managers, researchers, and technical support agencies who are seeking to scale-up health service innovations that have been tested in pilot projects or other field tests and proven successful.